Lacosamide Tablets (Strengths: 50mg, 100mg, MAH: Zhejiang Jiuzhou Biopharmaceutical Co., Ltd.) developed and manufactured by Huayi Pharma has received approval from the National Medical Products Administration (NMPA) for marketing! Leveraging its profound expertise in formulation technology and robust production capabilities, Huayi Pharma remains committed to delivering high-quality products and services, solidifying its position as a trusted global partner in the pharmaceutical industry.  

Lacosamide Tablets

Lacosamide is a sodium channel blocker with a novel mechanism of action, classified as a third-generation antiepileptic drug. It offers minimal side effects, bypasses hepatic metabolism, and exhibits no clinically significant drug-drug interactions with other antiepileptic agents. Its unique mechanism makes it a promising new therapeutic option for patients with partial-onset seizures.  

Lacosamide Tablets from UCB Pharma was originally approved by the EMA and FDA in 2008, which is administered twice daily without food restrictions. Clinically, they are indicated for the adjunctive treatment of partial-onset seizures in patients aged 4 and older. Currently, it is listed in China’s National Reimbursement Drug List (Category B) and included in the 7th Round of National Volume-Based Procurement (VBP).  

With exceptional technical prowess and reliable manufacturing capacity, Huayi Pharma has earned widespread acclaim and deep trust from clients and peers alike. We adhere to stringent quality standards and manufacturing practice, ensuring compliance and excellence at every stage of drug manufacturing to meet the most demanding client requirements. This successful NMPA approval marks a new milestone in the collaboration between Huayi Pharma and Jiuzhou Biopharma, rooted in shared vision and mutual trust.  

Looking ahead, Huayi Pharma looks forward to deepening cooperation with Jiuzhou Biopharma, exploring new collaborative frontiers, jointly driving innovation and progress in the pharmaceutical industry, and injecting strong impetus into the industry. We will continue to focus on the pharmaceutical field, adhering to the concept of efficient, high-quality, cost-controllable and trustworthy service, empowering more partners to achieve shared success and shape a brilliant future for the pharmaceutical industry!